Cargando…
Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review
Hepatoid adenocarcinoma of the lung (HAL) is extremely rare and standardized treatment strategy for HAL has not been established. Patients with unresectable HAL have a shorter survival time ranges from 1 to 36 months. Here, we reported a 65-year-old female patient with unresectable alpha-fetoprotein...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245476/ https://www.ncbi.nlm.nih.gov/pubmed/32547068 http://dx.doi.org/10.2147/OTT.S248226 |
_version_ | 1783537768216920064 |
---|---|
author | Chen, Lulu Han, Xue Gao, Yujuan Zhao, Qi Wang, Yongsheng Jiang, Ya Liu, Sisi Wu, Xue Miao, Liyun |
author_facet | Chen, Lulu Han, Xue Gao, Yujuan Zhao, Qi Wang, Yongsheng Jiang, Ya Liu, Sisi Wu, Xue Miao, Liyun |
author_sort | Chen, Lulu |
collection | PubMed |
description | Hepatoid adenocarcinoma of the lung (HAL) is extremely rare and standardized treatment strategy for HAL has not been established. Patients with unresectable HAL have a shorter survival time ranges from 1 to 36 months. Here, we reported a 65-year-old female patient with unresectable alpha-fetoprotein-producing HAL harboring KRAS-G12V and no other targetable driver mutations. The patient was treated with multiple lines of chemotherapies followed by PD-1 inhibitor, sintilimab, due to positive staining of PD-L1, and achieved an overall survival of 52 months. Although the disease was under control, the patient experienced fifth-grade pneumonia and died after 6 months of anti-PD-1 treatment. This is the first case of KRAS-positive HAL patient achieved stable disease by PD-1 inhibitor, which may provide valuable information for the treatment strategy development of advanced HAL patients, and highlights the importance of molecular diagnosis in treatment decision-making. |
format | Online Article Text |
id | pubmed-7245476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72454762020-06-15 Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review Chen, Lulu Han, Xue Gao, Yujuan Zhao, Qi Wang, Yongsheng Jiang, Ya Liu, Sisi Wu, Xue Miao, Liyun Onco Targets Ther Case Report Hepatoid adenocarcinoma of the lung (HAL) is extremely rare and standardized treatment strategy for HAL has not been established. Patients with unresectable HAL have a shorter survival time ranges from 1 to 36 months. Here, we reported a 65-year-old female patient with unresectable alpha-fetoprotein-producing HAL harboring KRAS-G12V and no other targetable driver mutations. The patient was treated with multiple lines of chemotherapies followed by PD-1 inhibitor, sintilimab, due to positive staining of PD-L1, and achieved an overall survival of 52 months. Although the disease was under control, the patient experienced fifth-grade pneumonia and died after 6 months of anti-PD-1 treatment. This is the first case of KRAS-positive HAL patient achieved stable disease by PD-1 inhibitor, which may provide valuable information for the treatment strategy development of advanced HAL patients, and highlights the importance of molecular diagnosis in treatment decision-making. Dove 2020-05-19 /pmc/articles/PMC7245476/ /pubmed/32547068 http://dx.doi.org/10.2147/OTT.S248226 Text en © 2020 Chen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Report Chen, Lulu Han, Xue Gao, Yujuan Zhao, Qi Wang, Yongsheng Jiang, Ya Liu, Sisi Wu, Xue Miao, Liyun Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review |
title | Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review |
title_full | Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review |
title_fullStr | Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review |
title_full_unstemmed | Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review |
title_short | Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review |
title_sort | anti-pd-1 therapy achieved disease control after multiline chemotherapy in unresectable kras-positive hepatoid lung adenocarcinoma: a case report and literature review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245476/ https://www.ncbi.nlm.nih.gov/pubmed/32547068 http://dx.doi.org/10.2147/OTT.S248226 |
work_keys_str_mv | AT chenlulu antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT hanxue antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT gaoyujuan antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT zhaoqi antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT wangyongsheng antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT jiangya antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT liusisi antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT wuxue antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview AT miaoliyun antipd1therapyachieveddiseasecontrolaftermultilinechemotherapyinunresectablekraspositivehepatoidlungadenocarcinomaacasereportandliteraturereview |